- Home
- JCI vs REGN Comparison
JCI vs REGN Comparison
Compare JCI & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCI
- REGN
- Stock Information
- Founded
- JCI 1885
- REGN 1988
- Country
- JCI Ireland
- REGN United States
- Employees
- JCI N/A
- REGN N/A
- Industry
- JCI Industrial Machinery/Components
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- JCI Industrials
- REGN Health Care
- Exchange
- JCI Nasdaq
- REGN Nasdaq
- Market Cap
- JCI 67.9B
- REGN 59.9B
- IPO Year
- JCI N/A
- REGN 1991
- Fundamental
- Price
- JCI $106.49
- REGN $558.87
- Analyst Decision
- JCI Buy
- REGN Buy
- Analyst Count
- JCI 15
- REGN 21
- Target Price
- JCI $107.79
- REGN $823.86
- AVG Volume (30 Days)
- JCI 5.0M
- REGN 940.4K
- Earning Date
- JCI 07-29-2025
- REGN 08-01-2025
- Dividend Yield
- JCI 1.39%
- REGN 0.63%
- EPS Growth
- JCI 41.38
- REGN 5.03
- EPS
- JCI 3.37
- REGN 39.67
- Revenue
- JCI $23,402,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- JCI $3.45
- REGN N/A
- Revenue Next Year
- JCI $4.98
- REGN $6.65
- P/E Ratio
- JCI $35.44
- REGN $14.09
- Revenue Growth
- JCI 14.26
- REGN 5.38
- 52 Week Low
- JCI $64.31
- REGN $476.49
- 52 Week High
- JCI $112.63
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- JCI 50.99
- REGN 54.16
- Support Level
- JCI $102.09
- REGN $541.61
- Resistance Level
- JCI $112.63
- REGN $563.59
- Average True Range (ATR)
- JCI 2.46
- REGN 15.37
- MACD
- JCI -0.67
- REGN -0.75
- Stochastic Oscillator
- JCI 41.75
- REGN 41.57
About JCI Johnson Controls International plc
Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).